Glecaprevir + Pibrentasvir interactions
Checked as Glecaprevir + Pibrentasvir in this data source.
Full monograph for Glecaprevir + PibrentasvirCheck it against another medicine
Medicines
135 documented
| Medicine | Severity | Mechanism | Effect | Sources |
|---|---|---|---|---|
| Amlodipine Besilate + Atorvastatinvia Glecaprevir | Major | Absorption · Distribution · Metabolism | Coadministration with glecaprevir-pibrentasvir may significantly increase the plasma concentrations of atorvastatin, simvastatin, and their active acid…2 documented mechanisms | 11 sources — open the full entry |
| Atorvastatin + Ezetimibevia Glecaprevir | Major | Absorption · Distribution · Metabolism | Coadministration with glecaprevir-pibrentasvir may significantly increase the plasma concentrations of atorvastatin, simvastatin, and their active acid…2 documented mechanisms | 11 sources — open the full entry |
| Atorvastatin Calciumvia Glecaprevir | Major | Absorption · Distribution · Metabolism | Coadministration with glecaprevir-pibrentasvir may significantly increase the plasma concentrations of atorvastatin, simvastatin, and their active acid…2 documented mechanisms | 11 sources — open the full entry |
| Carbamazepinevia Glecaprevir | Major | Metabolism | Coadministration with potent inducers of P-glycoprotein (P-gp) or CYP450 3A4 may significantly decrease the plasma concentrations of glecaprevir and…2 documented mechanisms | 6 sources — open the full entry |
| Colchicinevia Pibrentasvir, Glecaprevir | Major | Absorption · Excretion | Coadministration with inhibitors of P-glycoprotein (P-gp) may significantly increase the serum concentrations of colchicine. The mechanism involves enhanced…3 documented mechanisms | 107 sources — open the full entry |
| Cyclosporine (Oral)via Glecaprevir | Major | Absorption · Distribution · Metabolism | Coadministration with cyclosporine may significantly increase the plasma concentrations of glecaprevir. The proposed mechanism is inhibition of organic anion…2 documented mechanisms | 16 sources — open the full entry |
| Cyproterone Acetate + Ethinyl Estradiolvia Glecaprevir | Major | Metabolism · Synergy | Coadministration of ethinyl estradiol with glecaprevir-pibrentasvir may increase the risk of alanine aminotransferase (ALT) elevations. ALT elevations are also…2 documented mechanisms | 5 sources — open the full entry |
| Dabigatran Etexilate Mesylatevia Glecaprevir | Major | Excretion | Coadministration of dabigatran etexilate with glecaprevir-pibrentasvir may significantly increase the plasma concentrations of dabigatran. The proposed… | 1 sources — open the full entry |
| Drospirenone + Ethinyl Estradiol0.02 mg0.03 mgvia Glecaprevir | Major | Metabolism · Synergy | Coadministration of ethinyl estradiol with glecaprevir-pibrentasvir may increase the risk of alanine aminotransferase (ALT) elevations. ALT elevations are also…2 documented mechanisms | 5 sources — open the full entry |
| Drospirenone + Ethinyl Estradiol + Levomefolatevia Glecaprevir | Major | Metabolism · Synergy | Coadministration of ethinyl estradiol with glecaprevir-pibrentasvir may increase the risk of alanine aminotransferase (ALT) elevations. ALT elevations are also…2 documented mechanisms | 5 sources — open the full entry |
| Efavirenzvia Glecaprevir | Major | Metabolism | Coadministration with potent inducers of P-glycoprotein (P-gp) or CYP450 3A4 may significantly decrease the plasma concentrations of glecaprevir and…2 documented mechanisms | 6 sources — open the full entry |
| Ethinyl Estradiol + Desogestrel0.02 mg0.03 mgvia Glecaprevir | Major | Metabolism · Synergy | Coadministration of ethinyl estradiol with glecaprevir-pibrentasvir may increase the risk of alanine aminotransferase (ALT) elevations. ALT elevations are also…2 documented mechanisms | 5 sources — open the full entry |
| Ethinyl Estradiol + Gestodenevia Glecaprevir | Major | Metabolism · Synergy | Coadministration of ethinyl estradiol with glecaprevir-pibrentasvir may increase the risk of alanine aminotransferase (ALT) elevations. ALT elevations are also…2 documented mechanisms | 5 sources — open the full entry |
| Ethinyl Estradiol + Levonorgestrel + Ferrous Fumaratevia Glecaprevir | Major | Metabolism · Synergy | Coadministration of ethinyl estradiol with glecaprevir-pibrentasvir may increase the risk of alanine aminotransferase (ALT) elevations. ALT elevations are also…2 documented mechanisms | 5 sources — open the full entry |
| Ethinyl Estradiol + Lynestrenol0.0375 mg0.05 mgvia Glecaprevir | Major | Metabolism · Synergy | Coadministration of ethinyl estradiol with glecaprevir-pibrentasvir may increase the risk of alanine aminotransferase (ALT) elevations. ALT elevations are also…2 documented mechanisms | 5 sources — open the full entry |
| Morphine Sulfatevia Glecaprevir | Major | Absorption | Coadministration with P-glycoprotein (P-gp) inhibitors may increase the plasma concentrations of morphine and its risk of adverse effects, including… | 7 sources — open the full entry |
| Norgestrel + Ethinyl Estradiol + Ferrous Fumaratevia Glecaprevir | Major | Metabolism · Synergy | Coadministration of ethinyl estradiol with glecaprevir-pibrentasvir may increase the risk of alanine aminotransferase (ALT) elevations. ALT elevations are also…2 documented mechanisms | 5 sources — open the full entry |
| Pazopanib Hydrochloridevia Glecaprevir | Major | Absorption · Metabolism | Coadministration with potent inhibitors of P-glycoprotein (P-gp) or breast cancer resistance protein (BCRP) may significantly increase the plasma…2 documented mechanisms | 10 sources — open the full entry |
| Phenobarbitalvia Glecaprevir | Major | Metabolism | Coadministration with potent inducers of P-glycoprotein (P-gp) or CYP450 3A4 may significantly decrease the plasma concentrations of glecaprevir and…2 documented mechanisms | 6 sources — open the full entry |
| Phenytoin Sodiumvia Glecaprevir | Major | Metabolism | Coadministration with potent inducers of P-glycoprotein (P-gp) or CYP450 3A4 may significantly decrease the plasma concentrations of glecaprevir and…2 documented mechanisms | 6 sources — open the full entry |
| Pravastatin Sodiumvia Glecaprevir | Major | Distribution · Metabolism | Coadministration with glecaprevir-pibrentasvir may significantly increase the plasma concentrations of pravastatin. The proposed mechanism is inhibition of…2 documented mechanisms | 3 sources — open the full entry |
| Primidonevia Glecaprevir | Major | Metabolism | Coadministration with potent inducers of P-glycoprotein (P-gp) or CYP450 3A4 may significantly decrease the plasma concentrations of glecaprevir and…2 documented mechanisms | 6 sources — open the full entry |
| Relugolixvia Pibrentasvir, Glecaprevir | Major | Absorption | Coadministration with inhibitors of the P-glycoprotein (P-gp) efflux transporter may increase the plasma concentrations of relugolix, particularly when the…3 documented mechanisms | 3 sources — open the full entry |
| Relugolix + Estradiol + Norethindronevia Pibrentasvir, Glecaprevir | Major | Absorption | Coadministration with inhibitors of the P-glycoprotein (P-gp) efflux transporter may increase the plasma concentrations of relugolix, particularly when the…3 documented mechanisms | 3 sources — open the full entry |
| Rifampicinvia Glecaprevir | Major | Absorption · Distribution · Metabolism | The plasma concentrations of glecaprevir may increase significantly during acute coadministration with rifampin, but decreases after chronic coadministration…2 documented mechanisms | 3 sources — open the full entry |
| Rifampicin + Isoniazidvia Glecaprevir | Major | Absorption · Distribution · Metabolism | The plasma concentrations of glecaprevir may increase significantly during acute coadministration with rifampin, but decreases after chronic coadministration…2 documented mechanisms | 3 sources — open the full entry |
| Rifampicin + Isoniazid + Pyrazinamide + Ethambutolvia Glecaprevir | Major | Absorption · Distribution · Metabolism | The plasma concentrations of glecaprevir may increase significantly during acute coadministration with rifampin, but decreases after chronic coadministration…2 documented mechanisms | 3 sources — open the full entry |
| Rosuvastatin + Ezetimibevia Glecaprevir | Major | Absorption · Distribution · Metabolism | Coadministration with glecaprevir-pibrentasvir may significantly increase the plasma concentrations of rosuvastatin. The proposed mechanism is inhibition of…2 documented mechanisms | 3 sources — open the full entry |
| Rosuvastatin Calciumvia Glecaprevir | Major | Absorption · Distribution · Metabolism | Coadministration with glecaprevir-pibrentasvir may significantly increase the plasma concentrations of rosuvastatin. The proposed mechanism is inhibition of…2 documented mechanisms | 3 sources — open the full entry |
| Simvastatinvia Glecaprevir | Major | Absorption · Distribution · Metabolism | Coadministration with glecaprevir-pibrentasvir may significantly increase the plasma concentrations of atorvastatin, simvastatin, and their active acid…2 documented mechanisms | 11 sources — open the full entry |
| Venetoclaxvia Glecaprevir | Major | Absorption | Coadministration with P-glycoprotein (P-gp) inhibitors may increase the plasma concentrations of venetoclax, which is a substrate of this efflux transporter.2 documented mechanisms | 8 sources — open the full entry |
| Acarbosevia Pibrentasvir, Glecaprevir | Moderate | Synergy | Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered…2 documented mechanisms | 11 sources — open the full entry |
| Afatinib Dimaleatevia Pibrentasvir, Glecaprevir | Moderate | Distribution · Others | Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of afatinib, which is a substrate of the efflux transporter.3 documented mechanisms | 5 sources — open the full entry |
| Alogliptin Benzoatevia Pibrentasvir, Glecaprevir | Moderate | Synergy | Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered…2 documented mechanisms | 11 sources — open the full entry |
| Apalutamidevia Glecaprevir | Moderate | Metabolism | Coadministration with inducers of P-glycoprotein (P-gp) or CYP450 3A4 may decrease the plasma concentrations of glecaprevir and pibrentasvir. Both antiviral…2 documented mechanisms | 3 sources — open the full entry |
| Apixabanvia Pibrentasvir, Glecaprevir | Moderate | Metabolism | Coadministration with inhibitors of CYP450 3A4 and/or P-glycoprotein (P-gp) may increase the plasma concentrations of apixaban, which is a substrate of both…3 documented mechanisms | 5 sources — open the full entry |
| Armodafinilvia Glecaprevir | Moderate | Metabolism | Coadministration with inducers of P-glycoprotein (P-gp) or CYP450 3A4 may decrease the plasma concentrations of glecaprevir and pibrentasvir. Both antiviral…2 documented mechanisms | 3 sources — open the full entry |
| Bempedoic acidvia Glecaprevir | Moderate | Absorption · Excretion · Metabolism | Coadministration with bempedoic acid may increase the plasma concentrations and the risk of adverse effects of drugs that are substrates of the uptake…2 documented mechanisms | 5 sources — open the full entry |
| Bempedoic acid + Ezetimibevia Glecaprevir | Moderate | Absorption · Excretion · Metabolism | Coadministration with bempedoic acid may increase the plasma concentrations and the risk of adverse effects of drugs that are substrates of the uptake…2 documented mechanisms | 5 sources — open the full entry |
| Betrixabanvia Pibrentasvir, Glecaprevir | Moderate | Absorption · Excretion | Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of betrixaban, which is a substrate of the efflux transporter.3 documented mechanisms | 5 sources — open the full entry |
| Biphasic Insulin Aspartvia Pibrentasvir, Glecaprevir | Moderate | Synergy | Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered…2 documented mechanisms | 11 sources — open the full entry |
| Bosentan Monohydratevia Glecaprevir | Moderate | Metabolism | Coadministration with inducers of P-glycoprotein (P-gp) or CYP450 3A4 may decrease the plasma concentrations of glecaprevir and pibrentasvir. Both antiviral…2 documented mechanisms | 3 sources — open the full entry |
| Brigatinibvia Glecaprevir | Moderate | Metabolism | Coadministration with inducers of P-glycoprotein (P-gp) or CYP450 3A4 may decrease the plasma concentrations of glecaprevir and pibrentasvir. Both antiviral…2 documented mechanisms | 3 sources — open the full entry |
| Bromocriptine Mesylatevia Pibrentasvir, Glecaprevir | Moderate | Synergy | Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered…2 documented mechanisms | 11 sources — open the full entry |
| Calcium Dobesilate + Lidocaine + Dexamethasonevia Glecaprevir | Moderate | Metabolism | Coadministration with inducers of P-glycoprotein (P-gp) or CYP450 3A4 may decrease the plasma concentrations of glecaprevir and pibrentasvir. Both antiviral…2 documented mechanisms | 3 sources — open the full entry |
| Canagliflozin Hemihydratevia Pibrentasvir, Glecaprevir | Moderate | Synergy | Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered…2 documented mechanisms | 11 sources — open the full entry |
| Cenobamatevia Glecaprevir | Moderate | Metabolism | Coadministration with inducers of P-glycoprotein (P-gp) or CYP450 3A4 may decrease the plasma concentrations of glecaprevir and pibrentasvir. Both antiviral…2 documented mechanisms | 3 sources — open the full entry |
| Ciprofloxacin + Dexamethasonevia Glecaprevir | Moderate | Metabolism | Coadministration with inducers of P-glycoprotein (P-gp) or CYP450 3A4 may decrease the plasma concentrations of glecaprevir and pibrentasvir. Both antiviral…2 documented mechanisms | 3 sources — open the full entry |
| Dapagliflozin Propanediolvia Pibrentasvir, Glecaprevir | Moderate | Synergy | Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered…2 documented mechanisms | 11 sources — open the full entry |
| Darolutamidevia Glecaprevir | Moderate | Distribution · Metabolism | Coadministration with darolutamide may increase the plasma concentrations of drugs that are substrates of the organic anion transporting polypeptides (OATP)…2 documented mechanisms | 6 sources — open the full entry |
This source documents no food, condition or duplication entries for Glecaprevir + Pibrentasvir.